Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 28, 2010, Pages 12559-12563

  Lindzen, Moshit ^a   Lavi, Sara ^a   Leitner, Orith ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer therapy; Growth factor; Monoclonal antibody; Signal transduction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL GROWTH; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOTHERAPY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMALIA; MUS;

EID: 77955459829     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006218107     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
2. Harris RC, Chung E, Coffey RJ (2003) EGF receptor ligands. Exp Cell Res 284:2-13.
3. Falls DL (2003) Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res 284:14-30.
4. Klapper LN, et al. (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96:4995-5000.
5. Kochupurakkal BS, et al. (2005) Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280:8503-8512.
6. Jorissen RN, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53. (Pubitemid 36331965)
7. Barozzi C, et al. (2002) Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 94:647-657.
8. Thøgersen VB, et al. (2001) A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61:6227-6233.
9. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, Tweardy DJ (1998) Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69:55-62. (Pubitemid 28099922)
10. Wang F, et al. (2007) Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene 26: 2006-2016. (Pubitemid 46514736)
11. Eckstein N, et al. (2008) Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283:739-750.
12. Britten CD (2004) Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Mol Cancer Ther 3:1335-1342.
13. Weiner LM, Borghaei H (2006) Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. Hum Antibodies 15(3):103-111. (Pubitemid 44609980)
14. Ishikawa N, et al. (2005) Increases of amphiregulin and transforming growth factoralpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65:9176-9184.
15. Zhou BB, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39-50.
16. Valabrega G, et al. (2005) TGFalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene 24:3002-3010. (Pubitemid 40675531)
17. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
18. Ritter CA, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909-4919.
19. Bianchi S, et al. (2006) ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. J Cell Physiol 206:702-708.
20. Karamouzis MV, Badra FA, Papavassiliou AG (2007) Breast cancer: The upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 39:851-856. (Pubitemid 46575320)
21. Shih T, Lindley C (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802. (Pubitemid 46038527)
22. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342.
23. Van Zoelen EJ, Stortelers C, Lenferink AE, Van de Poll ML (2000) The EGF domain: Requirements for binding to receptors of the ErbB family. Vitam Horm 59:99-131.
24. Mackenzie RP, McCollum AD (2009) Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 9:1473-1485.
25. Harari PM, Wheeler DL, Grandis JR (2009) Molecular target approaches in head and neck cancer: Epidermal growth factor receptor and beyond. Semin Radiat Oncol 19: 63-68.
26. Citri A, Yarden Y (2006) EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7:505-516. (Pubitemid 44036456)
27. Ramnarain DB, et al. (2006) Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res 66:867-874.
28. Abdeen A, et al. (2009) Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115:5243-5250.
29. Heinemann V (2001) Gemcitabine: Progress in the treatment of pancreatic cancer. Oncology 60:8-18. (Pubitemid 32041425)
30. Fischer C, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463-475.
31. Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R (2008) Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int J Cancer 123:2939-2949.
32. Ferrer-Soler L, et al. (2007) An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20:3-10.
33. Bianco C, et al. (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258.
34. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA, Jr (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29(1, Suppl 4):37-46.
35. Eshhar Z, Ofarim M, Waks T (1980) Generation of hybridomas secreting murine reaginic antibodies of anti-DNP specificity. J Immunol 124:775-780. (Pubitemid 10135320)